Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04482478
Other study ID # NOVAKM_EDL
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2020
Est. completion date December 30, 2024

Study information

Verified date January 2024
Source Seoul National University Bundang Hospital
Contact Nayoung Kim, M.D., Ph. D.
Phone 82-31-787-7008
Email nayoung49@empas.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial was designed to evaluate the functional and safety effects on dyspeptic symptoms compared to the placebo when ingested with EDL (Extract of Dolichos lablab Linne) in adults who complain of dyspeptic symptoms.


Description:

Dyspepsia is a common disease and accounts for about 5% of all patients visiting primary care. Of these, about 70~90% of dyspeptic patients who visit the tertiary medical institution have functional digestion, considering that about 8~20% of dyspeptic patients who are referred from the primary medical institution to the tertiary medical institution are found. It is estimated to be bad. Functional dyspepsia is not life-threatening, but its symptoms persist throughout life and are not easily cured, which can limit social life and reduce the quality of life. Therefore, this clinical trial was designed to evaluate the functional and safety effects on dyspeptic symptoms compared to the placebo when ingested with EDL (Extract of Dolichos lablab Linne) in adults who complain of dyspeptic symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Those over the age of 19 2. Those diagnosed with functional dyspepsia (Rome IV*) * One or more of the following symptoms are diagnosed when there is no organic cause in the test including the upper gastrointestinal endoscopy(if symptoms begin 6 months prior to Visit 1, and the symptoms are present in the past 3 months). - Othersome postprandial fullness - Unpleasant early satiation - Unpleasant epigastric pain - Unpleasant epigastric burning 3. A person who has 4 or more of the 10 symptoms in the GIS (Gastrointestinal Symptom) questionnaire and has a total score of 12 or more (5-point Likert scale) 4. When there is no organic disease in the gastroscopy performed at Visit 1 (however, it can be replaced by the test results within 3 months from Visit 1) 5. A person who consented to participate in this clinical trial and signed a Informed consent form before the trail began. Exclusion Criteria: 1. Persons who are currently being treated with severe cardiovascular system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, nervous system, musculoskeletal system, mental, infectious diseases, and malignant tumors (however, considering the condition of the subjects, subjects can participate in the test according to investigator's judgment.) 2. Persons with a history of peptic ulcer and reflux esophagitis within 6 months of Visit 1 3. Those who have gastrointestinal surgery (except appendectomy and hemorrhoidectomy) 4. Persons with a history of malignancy of the digestive system 5. Those who have taken H2 receptor blockers, anticholinergic agents (muscarinic receptor antagonists), gastrin receptor antagonists, prostaglandin preparations, proton pump inhibitors, gastric mucosal protective agents, other drugs intended to treat gastritis, gastric health-related health functional food within 2 weeks of Visit 1 6. Those who need to constantly take medications that can cause gastritis, such as adrenal cortical hormones, nonsteroidal anti-inflammatory drugs, and aspirin during the human application test {However, low-dose aspirin for cardiovascular disease prevention (100 mg/day or less) permit} 7. In the Drinking Habit Questionnaire, those who had an average alcohol intake of 14 units or more for men and or more 7 units for women per week for the past month. 8. Uncontrolled hypertension persons (systolic blood pressure of 160 mmHg or higher, or diastolic blood pressure of 100 mmHg or higher, measurement criteria after 10 minutes of stability in human subjects) 9. Persons with uncontrolled diabetes (fasting blood sugar is over 180 mg/dL) 10. Those whose Creatinine is more than twice the normal upper limit of the study institution 11. Those whose AST(GOT) or ALT(GPT) is more than 3 times the normal upper limit of the study institution 12. Persons who are sensitive or allergic to investigational product for this clinical trial 13. Pregnant, lactating or planning to become pregnant within 3 months 14. Those who participated in other clinical trials within 3 months of Visit 1 or plan to participate in other clinical trials after the start of this clinical trials. 15. A person who determines that the Investigator is inappropriate for clinical trials 16. Employee of Department of Digestive Internal Medicine, Seoul National University Bundang Hospital

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Extract of Dolichos lablab Linne (EDL)
Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
Other:
Placebo oral tablet
Placebo: consumed in the same way as the investigational product

Locations

Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Bundang Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary GSRS(Gastrointestinal Symptom Rating Scale) Stomach symptom score GSRS (Gastrointestinal Symptom Rating Scale) Stomach symptom score change after 12 weeks of administration, compared to Baseline.
the unabbreviated scale title: Gastrointestinal Symptom Rating Scale
the minimum and maximum values: 0, 24
higher scores mean a worse outcome.
12 weeks
Secondary GSRS(Gastrointestinal Symptom Rating Scale) Stomach symptom score GSRS (Gastrointestinal Symptom Rating Scale) Stomach symptom score change after 6 weeks of administration, compared to Baseline.
the unabbreviated scale title: Gastrointestinal Symptom Rating Scale
the minimum and maximum values: 0, 24
higher scores mean a worse outcome.
6 weeks
Secondary GSRS(Gastrointestinal Symptom Rating Scale) Total score GSRS (Gastrointestinal Symptom Rating Scale) Total score change after 6 weeks, 12 weeks of administration, compared to Baseline.
the unabbreviated scale title: Gastrointestinal Symptom Rating Scale
the minimum and maximum values: 0, 45
higher scores mean a worse outcome.
6 weeks, 12 weeks
Secondary GIS(Gastrointestinal Symptom) GIS(Gastrointestinal Symptom) score change after 6 weeks, 12 weeks of administration, compared to Baseline.
the unabbreviated scale title: Gastrointestinal Symptom
the minimum and maximum values: 0, 40
higher scores mean a worse outcome.
6 weeks, 12 weeks
Secondary FD-QoL(Functional Dyspepsia-Related Quality of Life) FD-QoL(Functional Dyspepsia-Related Quality of Life) score change after 12 weeks of administration, compared to Baseline.
the unabbreviated scale title: Functional Dyspepsia-Related Quality of Life
the minimum and maximum values: 0, 84
higher scores mean a worse outcome.
12 weeks
Secondary ESR(Erythrocyte Sedimentation Rate) ESR(Erythrocyte Sedimentation Rate) change after 6 weeks, 12 weeks of administration, compared to Baseline. 6 weeks, 12 weeks
Secondary CRP(C-Reactive Protein) CRP(C-Reactive Protein) change after 6 weeks, 12 weeks of administration, compared to Baseline. 6 weeks, 12 weeks
Secondary IFN-?(Interferon) IFN-?(Interferon) change after 12 weeks of administration, compared to Baseline. 12 weeks
Secondary TNF-a(Tumor necrosis factors) TNF-a(Tumor necrosis factors) change after 12 weeks of administration, compared to Baseline. 12 weeks
Secondary 8-OhdG(8-Oxo-2'-deoxyguanosine) 8-OhdG(8-Oxo-2'-deoxyguanosine) change after 12 weeks of administration, compared to Baseline. 12 weeks
Secondary TAS(total antioxidnat status) TAS(total antioxidnat status) change after 12 weeks of administration, compared to Baseline. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04464369 - Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial Phase 4
Completed NCT01671670 - Acupuncture for Patients With Function Dyspepsia Phase 2/Phase 3
Completed NCT00987805 - Efficacy of Banhasasim-tang on Functional Dyspepsia Phase 4
Completed NCT00693407 - Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation N/A
Completed NCT00761358 - To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia Phase 3
Recruiting NCT01240096 - Mirtazapine Versus Placebo in Functional Dyspepsia Phase 4
Recruiting NCT04540549 - Effects of Exercise on Functional Dyspepsia Based on Rome IV N/A
Recruiting NCT03652571 - Nortriptyline for the Treatment of Functional Dyspepsia Phase 3
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Recruiting NCT03825692 - International Clinical Study of Zhizhu Kuanzhong Capsule Phase 4
Not yet recruiting NCT04548011 - Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia N/A
Terminated NCT02567578 - A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia Phase 2
Completed NCT03007433 - Assessment of GI Function to a Large Test Meal by Non-invasive Imaging N/A
Active, not recruiting NCT00990405 - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Phase 4
Completed NCT00404534 - Helicobacter Eradication Relief of Dyspeptic Symptoms Phase 3
Completed NCT03043625 - Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia N/A
Completed NCT03225248 - Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia Phase 3
Recruiting NCT05587127 - Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia N/A
Recruiting NCT01021475 - Does Visceral Manipulation Works in Treating Functional Dyspepsia? Phase 1